skip to content


Genus collaboration with Caribou Biosciences

18 May 2016 09:24

Genus and Caribou Biosciences have announced a multi-year strategic collaboration where Genus receives a worldwide, exclusive licence to Caribou's leading CRISPR-Cas9 gene editing technology platform in certain livestock species.

This is a significant move for Genus and marks the largest technology-driven alliance that Genus has made to date.

The partnership positions Caribou at the forefront of an emerging market for which CRISPR-Cas9 could have profound benefits to animal welfare and society.

At 9:24am: (LON:GNS) Genus PLC share price was -42.5p at 1527.5p

Story provided by

Related Company: GNS

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.